Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$1.2 million.

  • Evoke Pharma's Net Income towards Common Stockholders rose 1190.06% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 1497.85%. This contributed to the annual value of -$5.4 million for FY2024, which is 3131.43% up from last year.
  • Latest data reveals that Evoke Pharma reported Net Income towards Common Stockholders of -$1.2 million as of Q3 2025, which was up 1190.06% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Net Income towards Common Stockholders registered a high of -$1.2 million during Q3 2025, and its lowest value of -$2.7 million during Q1 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$1.8 million (2022), whereas its average is -$1.8 million.
  • As far as peak fluctuations go, Evoke Pharma's Net Income towards Common Stockholders skyrocketed by 6712.34% in 2021, and later tumbled by 2397.05% in 2025.
  • Over the past 5 years, Evoke Pharma's Net Income towards Common Stockholders (Quarter) stood at -$1.7 million in 2021, then fell by 7.82% to -$1.8 million in 2022, then dropped by 10.21% to -$2.0 million in 2023, then skyrocketed by 39.98% to -$1.2 million in 2024, then increased by 3.06% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.3 million during Q1 2025.